120. A Randomized Double-blind Trial Assessing the Efficacy of M72/AS01(E) Vaccine Against Pulmonary Tuberculosis Disease in Adults With Latent Mycobacterium tuberculosis Infection

BACKGROUND: An effective tuberculosis (TB) vaccine is urgently needed to support the End TB Strategy to reduce the number of new TB cases by 80% by 2030. M72/AS01(E) candidate vaccine is an adjuvanted recombinant fusion protein derived from Mycobacterium tuberculosis Mtb32A and Mtb39A proteins. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Meeren, Olivier Van Der, Hatherill, Mark, Nduba, Videlis, Wilkinson, Robert J, Muyoyeta, Monde, Van Brakel, Elana, Ayles, Helen M, Henostroza, German, Thienemann, Friedrich, Scriba, Thomas J, Diacon, Andreas, Blatner, Gretta L, Demoitié, Marie-Ange, Tameris, Michele, Malahleha, Mookho, Innes, James C, Hellstrom, Elizabeth, Martinson, Neil, Singh, Tina, Akite, Elaine J, Azam, Aisha K, Bollaerts, Anne, Ginsberg, Ann M, Evans, Thomas G, Gillard, Paul, Tait, Dereck R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253070/
http://dx.doi.org/10.1093/ofid/ofy209.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253070/
http://dx.doi.org/10.1093/ofid/ofy209.011

Ejemplares similares